3 results on '"Peter Gatehouse"'
Search Results
2. Cardiovascular magnetic resonance predictors of heart failure in hypertrophic cardiomyopathy: the role of myocardial replacement fibrosis and the microcirculation
- Author
-
Claire E. Raphael, Frances Mitchell, Gajen Sunthar Kanaganayagam, Alphonsus C. Liew, Elisa Di Pietro, Miguel Silva Vieira, Lina Kanapeckaite, Simon Newsome, John Gregson, Ruth Owen, Li-Yueh Hsu, Vassilis Vassiliou, Robert Cooper, Aamir Ali MRCP, Tevfik F. Ismail, Brandon Wong, Kristi Sun, Peter Gatehouse, David Firmin, Stuart Cook, Michael Frenneaux, Andrew Arai, Rory O’Hanlon, Dudley J. Pennell, and Sanjay K. Prasad
- Subjects
Hypertrophic cardiomyopathy ,Heart failure ,Prognosis ,Cardiovascular magnetic resonance ,Fibrosis ,Microvascular ischemia ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Introduction Heart failure (HF) in hypertrophic cardiomyopathy (HCM) is associated with high morbidity and mortality. Predictors of HF, in particular the role of myocardial fibrosis and microvascular ischemia remain unclear. We assessed the predictive value of cardiovascular magnetic resonance (CMR) for development of HF in HCM in an observational cohort study. Methods Serial patients with HCM underwent CMR, including adenosine first-pass perfusion, left atrial (LA) and left ventricular (LV) volumes indexed to body surface area (i) and late gadolinium enhancement (%LGE- as a % of total myocardial mass). We used a composite endpoint of HF death, cardiac transplantation, and progression to NYHA class III/IV. Results A total of 543 patients with HCM underwent CMR, of whom 94 met the composite endpoint at baseline. The remaining 449 patients were followed for a median of 5.6 years. Thirty nine patients (8.7%) reached the composite endpoint of HF death (n = 7), cardiac transplantation (n = 2) and progression to NYHA class III/IV (n = 20). The annual incidence of HF was 2.0 per 100 person-years, 95% CI (1.6–2.6). Age, previous non-sustained ventricular tachycardia, LV end-systolic volume indexed to body surface area (LVESVI), LA volume index ; LV ejection fraction, %LGE and presence of mitral regurgitation were significant univariable predictors of HF, with LVESVI (Hazard ratio (HR) 1.44, 95% confidence interval (95% CI) 1.16–1.78, p = 0.001), %LGE per 10% (HR 1.44, 95%CI 1.14–1.82, p = 0.002) age (HR 1.37, 95% CI 1.06–1.77, p = 0.02) and mitral regurgitation (HR 2.6, p = 0.02) remaining independently predictive on multivariable analysis. The presence or extent of inducible perfusion defect assessed using a visual score did not predict outcome (p = 0.16, p = 0.27 respectively). Discussion The annual incidence of HF in a contemporary ambulatory HCM population undergoing CMR is low. Myocardial fibrosis and LVESVI are strongly predictive of future HF, however CMR visual assessment of myocardial perfusion was not.
- Published
- 2021
- Full Text
- View/download PDF
3. T 1 mapping performance and measurement repeatability: results from the multi-national T 1 mapping standardization phantom program (T1MES)
- Author
-
Gabriella Captur, Abhiyan Bhandari, Rüdiger Brühl, Bernd Ittermann, Kathryn E. Keenan, Ye Yang, Richard J. Eames, Giulia Benedetti, Camilla Torlasco, Lewis Ricketts, Redha Boubertakh, Nasri Fatih, John P. Greenwood, Leonie E. M. Paulis, Chris B. Lawton, Chiara Bucciarelli-Ducci, Hildo J. Lamb, Richard Steeds, Steve W. Leung, Colin Berry, Sinitsyn Valentin, Andrew Flett, Charlotte de Lange, Francesco DeCobelli, Magalie Viallon, Pierre Croisille, David M. Higgins, Andreas Greiser, Wenjie Pang, Christian Hamilton-Craig, Wendy E. Strugnell, Tom Dresselaers, Andrea Barison, Dana Dawson, Andrew J. Taylor, François-Pierre Mongeon, Sven Plein, Daniel Messroghli, Mouaz Al-Mallah, Stuart M. Grieve, Massimo Lombardi, Jihye Jang, Michael Salerno, Nish Chaturvedi, Peter Kellman, David A. Bluemke, Reza Nezafat, Peter Gatehouse, James C. Moon, and on behalf of the T1MES Consortium
- Subjects
T 1 mapping ,Standardization ,Calibration ,Phantom ,Repeatability ,Extracellular volume ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background The T 1 Mapping and Extracellular volume (ECV) Standardization (T1MES) program explored T 1 mapping quality assurance using a purpose-developed phantom with Food and Drug Administration (FDA) and Conformité Européenne (CE) regulatory clearance. We report T 1 measurement repeatability across centers describing sequence, magnet, and vendor performance. Methods Phantoms batch-manufactured in August 2015 underwent 2 years of structural imaging, B 0 and B 1, and “reference” slow T 1 testing. Temperature dependency was evaluated by the United States National Institute of Standards and Technology and by the German Physikalisch-Technische Bundesanstalt. Center-specific T 1 mapping repeatability (maximum one scan per week to minimum one per quarter year) was assessed over mean 358 (maximum 1161) days on 34 1.5 T and 22 3 T magnets using multiple T 1 mapping sequences. Image and temperature data were analyzed semi-automatically. Repeatability of serial T 1 was evaluated in terms of coefficient of variation (CoV), and linear mixed models were constructed to study the interplay of some of the known sources of T 1 variation. Results Over 2 years, phantom gel integrity remained intact (no rips/tears), B 0 and B 1 homogenous, and “reference” T 1 stable compared to baseline (% change at 1.5 T, 1.95 ± 1.39%; 3 T, 2.22 ± 1.44%). Per degrees Celsius, 1.5 T, T 1 (MOLLI 5s(3s)3s) increased by 11.4 ms in long native blood tubes and decreased by 1.2 ms in short post-contrast myocardium tubes. Agreement of estimated T 1 times with “reference” T 1 was similar across Siemens and Philips CMR systems at both field strengths (adjusted R 2 ranges for both field strengths, 0.99–1.00). Over 1 year, many 1.5 T and 3 T sequences/magnets were repeatable with mean CoVs
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.